Search results (187)
« Back to NewsEnara Bio’s DARKFOX discovery propels ENA101, the first ever bispecific T Cell engager targeting a cancer-specific dark antigen, into IND-enabling studies
4 November 2025
Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumours, will unveil its newly discovered cancer-specific target DARKFOX™ as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in National Harbor, MD.
Partnership with CyanoCapture Ltd to develop bionanotechnology for targeted drug delivery
31 October 2025
The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based targeted drug delivery systems, exploiting unique traits found in fast-growing cyanobacteria.
U-Ploid presents first Lyvanta™ data demonstrating reduction of aneuploidy in aged oocytes at ASRM 2025
27 October 2025
U-Ploid is today presenting its first scientific abstract, “Preclinical testing of a novel therapeutic for reduction of aneuploidy in oocytes,” at the 2025 American Society for Reproductive Medicine (ASRM) Annual Meeting in San Antonio, Texas. The study showcases preclinical data on Lyvanta™ (UP-085), a novel therapeutic designed to reduce chromosome segregation errors in oocytes associated with maternal age.
Exogene Graduates from the BioEscalator
15 October 2025
We are delighted to celebrate the graduation of Exogene as it transitions from the BioEscalator to its new home at the Wood Centre for Innovation.
Simon Meier will be joining Oxford Cancer Analytics (OXcan) as Incoming Interim CEO
14 October 2025
Simon brings over two decades of strategic leadership and investment expertise across diagnostics, biotech, and digital health innovation.
Dr.Peter Jianrui Liu to step down as CEO of Oxford Cancer Analytics Ltd (OXcan)
10 October 2025
Dr. Peter Jianrui Liu, Co-Founder of OXcan, has decided to step down from his role as the Company’s Founding CEO, to pursue other interests. He will remain a significant shareholder in the Company and therefore will retain every interest in the Company’s development and success as an advisor.
Professor Heidi Johansen-Berg joins the BioEscalator Management Board
8 October 2025
We are delighted to welcome Professor Heidi Johansen-Berg to our Management Board, an expert in brain imaging and neuroplasticity, and a champion of innovation in the life sciences.
Theolytics appoints experienced medical oncologist Matilde Saggese, MD, as Chief Medical Officer
6 October 2025
Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260. THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer.
PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients
23 September 2025
53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing. PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity
PepGen Announces Pricing of $100 Million Public Offering
23 September 2025
PepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.
Moa and Nufarm announce next phase for their novel mode of action herbicide
17 September 2025
First phase completed a year earlier than typical industry timelines
Oxford Cancer Analytics featured in CTV News
12 September 2025
In the piece, CEO and co-founder Dr. Peter Jianrui Liu shares how the company is pioneering a non-invasive blood test for the early detection of lung cancer, using proteomics and AI/ML. Oxford Cancer Analytics' technology aims to change the way cancers are diagnosed, detecting disease earlier, cutting costs for health systems, and most importantly, saving lives.
BioEscalator Bulletin - Autumn 2025
10 September 2025
Stay informed with the latest BioEscalator updates, tenant and alumni news in the Autumn 2025 edition of the BioEscalator Bulletin.
Omos Biosciences joins the BioEscalator community to tackle cancer earlier
9 September 2025
We are delighted to welcome Omos Biosciences as the newest member of the BioEscalator community. The company has ambitious plans to transform cancer prevention by intervening at the pre-cancerous stage.
Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension
8 September 2025
Follows successful completion of pre-clinical activities by Alchemab as part of an earlier licensing deal with Eli Lilly and Company for ATLX-1282. Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors.
OMass Therapeutics enters into exclusive collaboration and license agreement with Genentech to develop and commercialise therapies for inflammatory bowel disease
1 September 2025
Collaboration leverages OMass’ OdyssionTM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease. OMass to receive $20M upfront payment, with potential for more than $400M in additional milestone payments, as well as tiered royalties on net sales.
Moa develops groundbreaking category of crop protection; signs partnership deal with Gowan
25 August 2025
OXFORD UK: Moa Technology today announces its discovery of chemistries which could become an entirely new category of products to help farmers protect their harvests more safely, sustainably and effectively.
Green is the new gold: Infinitopes awarded gold LEAF accreditation
21 August 2025
Infinitopes has achieved the gold standard among the latest awardees for the Laboratory Efficiency Assessment Framework (LEAF), an innovative initiative to improve laboratory efficiency. As the second BioEscalator tenant to earn this accreditation, they follow in the footsteps of 2023/24 winner, Exogene.
Congratulations Alethiomics, the BioEscalator’s most recent graduate
19 August 2025
We’re proud to celebrate the graduation of Alethiomics, a University of Oxford spin-out dedicated to developing innovative treatments for blood cancers, as they move from the BioEscalator to their new home at Abingdon Science Park.
Innovate UK awards Icosphere Biomedical Catalyst grant
19 August 2025
Icosphere Biosciences Awarded Innovate UK Biomedical Catalyst Grant to Develop Breakthrough Gene Therapy Vector Manufacturing Technology.